Let-7b Inhibits Cancer-promoting Effects of Breast Cancer-associated Fibroblasts Through IL-8 Repression
Overview
Affiliations
Cancer-associated fibroblasts (CAFs) are major players in the development and spread of breast carcinomas through non-cell-autonomous signaling. These paracrine effects are under the control of several genes and microRNAs. We present here clear evidence that let-7b, a tumor suppressor microRNA, plays key roles in the persistent activation of breast stromal fibroblasts and their functional interplay with cancer cells. We have first shown that let-7b is down-regulated in CAFs as compared to their corresponding normal adjacent fibroblasts, and transient specific let-7b inhibition permanently activated breast fibroblasts through induction of the IL-6-related positive feedback loop. More importantly, let-7b-deficient cells promoted the epithelial-to-mesenchymal transition process in breast cancer cells in an IL-8-dependent manner, and also enhanced orthotopic tumor growth . On the other hand, overexpression of let-7b by mimic permanently suppressed breast myofibroblasts through blocking the positive feedback loop, which inhibited their paracrine pro-carcinogenic effects. Furthermore, we have shown that let-7b negatively controls IL-8, which showed higher expression in the majority of CAF cells as compared to their adjacent normal counterparts, indicating that IL-8 plays a major role in the carcinoma/stroma cross-talk. These findings support targeting active stromal fibroblasts through restoration of let-7b/IL-8 expression as a therapeutic option for breast carcinomas.
Famta P, Shah S, Dey B, Kumar K, Bagasariya D, Vambhurkar G Cancer Pathog Ther. 2025; 3(1):30-47.
PMID: 39872366 PMC: 11764040. DOI: 10.1016/j.cpt.2024.01.001.
Let-7b-5p sensitizes breast cancer cells to doxorubicin through Aurora Kinase B.
Kaya M, Abuaisha A, Suer I, Emiroglu S, Onder S, Onay Ucar E PLoS One. 2025; 20(1):e0307420.
PMID: 39787178 PMC: 11717257. DOI: 10.1371/journal.pone.0307420.
Plasma miR-1-3p levels predict severity in hospitalized COVID-19 patients.
Di Pietro P, Abate A, Izzo C, Toni A, Rusciano M, Folliero V Br J Pharmacol. 2024; 182(2):451-467.
PMID: 39572402 PMC: 11791538. DOI: 10.1111/bph.17392.
Moro J, Grinpelc A, Farre P, Duca R, Lacunza E, Grana K Int J Mol Sci. 2023; 24(23).
PMID: 38069080 PMC: 10706566. DOI: 10.3390/ijms242316758.
Chiorino G, Petracci E, Sehovic E, Gregnanin I, Camussi E, Mello-Grand M Sci Rep. 2023; 13(1):12040.
PMID: 37491482 PMC: 10368693. DOI: 10.1038/s41598-023-38886-0.